|
The Indian Pharmaceutical Alliance (IP Alliance) will host the 11th edition of the Global Pharmaceutical Quality Summit (GPQS) between February 23 and 24, 2026, in Mumbai, centred on the theme “Reimagining Pharma Operations - Talent, Technology and Trust”.
J P Nadda, Union minister for health & family welfare and minister of chemicals & fertilizers, will deliver the keynote address in the inaugural session. Dr Rajeev Singh Raghuvanshi, Drugs Controller General of India (DCGI), will offer the inaugural remarks. Nilesh Gupta, managing director, Lupin, and chair, IP Alliance Quality Forum, will present the opening industry address. The concluding address will be delivered by Manoj Joshi, secretary, Department of Pharmaceuticals (DoP).
The Summit serves as a premier platform for thought leadership, collaboration, and knowledge exchange, shaping the future of pharmaceutical manufacturing and quality excellence.
The theme “Reimagining Pharma Operations – Talent, Technology and Trust” reflects the shift of pharmaceutical quality from a compliance requirement to a deeply embedded quality culture. By empowering skilled talent, leveraging advanced technologies, and building trust, the industry is redefining quality to meet rising global standards and make operations more resilient.
This edition will feature around 12 high-impact sessions with eminent speakers, including representatives from the US Food and Drug Administration (FDA), Medicines and Healthcare products Regulatory Agency (MHRA), and Central Drugs Standard Control Organisation (CDSCO), alongside global industry and consulting experts. Highlights include a CEO panel discussion, dedicated sessions featuring CIO/CTO leadership, and perspectives from advanced manufacturing and technology leaders, with a focus on AI-enabled and digitally integrated operations, fostering cross-sector learning.
The Summit will also witness the launch of two IP Alliance Industry Best Practices Guidelines aimed at strengthening quality and compliance across the value chain: Best practices in logistics and transportation worthiness for pharmaceutical product packaging and best practices in sustainability in the pharmaceutical industry.
In addition, IP Alliance will introduce the Lifetime Achievement Award in Academia, recognising distinguished contributions to pharmaceutical science and quality, and the Hackathon Winning Presentation, spotlighting innovation and emerging talent in quality advancement.
Sudarshan Jain, secretary general, Indian Pharmaceutical Alliance, said, “Quality is the foundation of the pharmaceutical industry and the most important promise we make to patients worldwide. Through the 11th edition of the Global Pharmaceutical Quality Summit, IP Alliance aims to reimagine the future of quality by focusing on the intersection of talent, technology and trust. The insights from these deliberations will help shape future-ready quality and operations frameworks and support India’s continued evolution as a trusted global pharmaceutical partner.”
The IP Alliance represents 23 leading national pharmaceutical companies committed to advancing innovation, improving access to healthcare, and contributing to economic growth. Together, IPA members account for over 85% of private sector investment in pharmaceutical research and development, drive more than 80% of India’s drug and pharmaceutical exports, and serve over 64% of the domestic market. Through policy advocacy, regulatory excellence, and industry collaboration, IP Alliance works to strengthen India’s position as the Pharmacy of the World.
|